Oncolytics Biotech, Inc (NASDAQ:ONCY) price on Tuesday, December 24, rose 7.09% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.97.
A look at the stock’s price movement, the close in the last trading session was $0.91, moving within a range at $0.885 and $0.9887. The beta value (5-Year monthly) was 1.506. Turning to its 52-week performance, $1.53 and $0.71 were the 52-week high and 52-week low respectively. Overall, ONCY moved 2.71% over the past month.
Oncolytics Biotech, Inc’s market cap currently stands at around $74.76 million, with investors looking forward to this quarter’s earnings report slated for in January.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ONCY is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend ONCY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ONCY’s current price about 11.39% and -5.66% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.55, while 7-day volatility ratio is 15.90% and 7.70% in the 30-day chart. Further, Oncolytics Biotech, Inc (ONCY) has a beta value of 1.30, and an average true range (ATR) of 0.07.
If we refocus on Oncolytics Biotech, Inc (NASDAQ:ONCY), historical trading data shows that trading volumes averaged 0.8 over the past 10 days and 561.69K over the past 3 months. The company’s latest data on shares outstanding shows there are 77.07 million shares.
The 1.40% of Oncolytics Biotech, Inc’s shares are in the hands of company insiders while institutional holders own 1.62% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.81 million on 2024-10-31, giving us a short ratio of 3.51. The data shows that as of 2024-10-31 short interest in Oncolytics Biotech, Inc (ONCY) stood at 389.00003 of shares outstanding, with shares short rising to 1.02 million registered in 2024-09-30. Current price change has pushed the stock -27.41% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ONCY stock continues to rise going into the next quarter.
